Researchers identified a previously unknown placental molecular process disrupted by gestational diabetes, helping explain pregnancy complications and long-term health risks for children.

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

A study published in Engineering shows that a protein called U2 small nuclear RNA auxiliary factor 1 (U2AF1), released by ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

A new study in Engineering reveals how macrophage-released U2AF1 aids heart repair after heart attack by steering Yap1 splicing toward the ...

Rznomics Inc. continued South Korea’s year-end biotech rally with a ₩46.35 billion (US$31.35 million) IPO Dec. 18. Proceeds will fund Seongnam-si, South Korea-based Rznomic’s pipeline of gene ...

Gestational diabetes can cause a multitude of complications in the offspring, but to date, the reasons are incompletely ...

Watch the “What This Means” video hereTAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an ...

Circular RNAs (circRNAs), recognized as covalently closed, single-stranded RNA molecules formed through reverse splicing, are characterized by their unique ring structures, site-specific splicing, and ...

The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSCLC and the CLK inhibitor in certain blood cancers.

Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFR TM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel ...